M Ferrante, L Siproudhis, G Poggioli, M Reinshagen, S Milicevic, M Roset, N BentEnnakhil, A Fernandez-Nistal, J Panes
{"title":"Treatment patterns and outcomes of patients with complex Crohn's perianal fistula in five European countries: the PREFACE study.","authors":"M Ferrante, L Siproudhis, G Poggioli, M Reinshagen, S Milicevic, M Roset, N BentEnnakhil, A Fernandez-Nistal, J Panes","doi":"10.51821/87.4.13143","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and study aims: </strong>Crohn's disease (CD) is often complicated by perianal fistulas or abscesses that worsen patient's quality of life, with 52-88% of CD-related perianal fistulas (CPFs) being complex. This retrospective study describes sociodemographic characteristics, treatment patterns and outcomes of patients with complex CPFs in five European countries.</p><p><strong>Patients and methods: </strong>PREFACE is a multi-national medical chart review study of CD patients who started medical or surgical treatment for a new episode of complex CPFs between September 2011 and September 2014 (index date). Effectiveness outcomes were assessed as fistula remission rates based on fistula drainage assessment. The most recent assessments prior to each timepoint were used to calculate fistula remission rates.</p><p><strong>Results: </strong>In total, 372 patients (51.3% male, mean age at index date 37.8 years) with 498 complex CPFs between index date and end of data collection were included. A quarter of patients with CPF already had perianal fistulas at CD diagnosis. Of the complex index CPFs, 39.8% were treated with antitumour necrosis factor, 33.3% with antibiotics and 16.3% with immunosuppressants. At least one surgery was performed for 93.8% of complex CPFs. By end of follow-up (median (IQR) 6.0 (5.2, 6.9) years), 61.2% of complex CPFs were not draining anymore. Fistula remission rate at patient level was 28.0% after 6 months, 35.2% after 12 months and 64.8% overall.</p><p><strong>Conclusions: </strong>Current therapeutic algorithms for CPFs are not successful in a considerable proportion of patients. Improved therapeutic strategies and new treatment options are required to achieve better outcomes in complex CPFs.</p>","PeriodicalId":7322,"journal":{"name":"Acta gastro-enterologica Belgica","volume":"87 4","pages":"494-504"},"PeriodicalIF":1.3000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta gastro-enterologica Belgica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.51821/87.4.13143","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background and study aims: Crohn's disease (CD) is often complicated by perianal fistulas or abscesses that worsen patient's quality of life, with 52-88% of CD-related perianal fistulas (CPFs) being complex. This retrospective study describes sociodemographic characteristics, treatment patterns and outcomes of patients with complex CPFs in five European countries.
Patients and methods: PREFACE is a multi-national medical chart review study of CD patients who started medical or surgical treatment for a new episode of complex CPFs between September 2011 and September 2014 (index date). Effectiveness outcomes were assessed as fistula remission rates based on fistula drainage assessment. The most recent assessments prior to each timepoint were used to calculate fistula remission rates.
Results: In total, 372 patients (51.3% male, mean age at index date 37.8 years) with 498 complex CPFs between index date and end of data collection were included. A quarter of patients with CPF already had perianal fistulas at CD diagnosis. Of the complex index CPFs, 39.8% were treated with antitumour necrosis factor, 33.3% with antibiotics and 16.3% with immunosuppressants. At least one surgery was performed for 93.8% of complex CPFs. By end of follow-up (median (IQR) 6.0 (5.2, 6.9) years), 61.2% of complex CPFs were not draining anymore. Fistula remission rate at patient level was 28.0% after 6 months, 35.2% after 12 months and 64.8% overall.
Conclusions: Current therapeutic algorithms for CPFs are not successful in a considerable proportion of patients. Improved therapeutic strategies and new treatment options are required to achieve better outcomes in complex CPFs.
期刊介绍:
The Journal Acta Gastro-Enterologica Belgica principally publishes peer-reviewed original manuscripts, reviews, letters to editors, book reviews and guidelines in the field of clinical Gastroenterology and Hepatology, including digestive oncology, digestive pathology, as well as nutrition. Pure animal or in vitro work will not be considered for publication in the Journal. Translational research papers (including sections of animal or in vitro work) are considered by the Journal if they have a clear relationship to or relevance for clinical hepato-gastroenterology (screening, disease mechanisms and/or new therapies). Case reports and clinical images will be accepted if they represent an important contribution to the description, the pathogenesis or the treatment of a specific gastroenterology or liver problem. The language of the Journal is English. Papers from any country will be considered for publication. Manuscripts submitted to the Journal should not have been published previously (in English or any other language), nor should they be under consideration for publication elsewhere. Unsolicited papers are peer-reviewed before it is decided whether they should be accepted, rejected, or returned for revision. Manuscripts that do not meet the presentation criteria (as indicated below) will be returned to the authors. Papers that go too far beyond the scope of the journal will be also returned to the authors by the editorial board generally within 2 weeks. The Journal reserves the right to edit the language of papers accepted for publication for clarity and correctness, and to make formal changes to ensure compliance with AGEB’s style. Authors have the opportunity to review such changes in the proofs.